– UK, London – LiDCO Group Plc (LON: LID), the hemodynamic monitoring company, today announced the appointment of James G. Wetrich to the Board, as a Non-Executive Director, with immediate effect.
Matt Sassone, CEO LiDCO, said: “The US represents the greatest opportunity for LiDCO’s future growth. James’ breadth of industry knowledge, contacts and experience in the US market brings to the Board additional skills to take Company forward.”
About James Wetrich
James brings with him over 35 years of experience in the US healthcare industry having worked both in the medical device and healthcare provider sectors, including companies such as Abbott Laboratories, Molnlycke Healthcare, Premier Inc, and Providence Health & Services. In the mid-1980s, James played an instrumental role in the formation of the University HealthSystem Consortium, now part of Vizient. This extensive work in the US healthcare supply chain has resulted in expert knowledge of the purchasing cycle including value analysis, strategic sourcing, supply chain relationship building and procurement logistics.
About LiDCO Group Plc
LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO’s products facilitate the application of hemodynamic optimisation protocols for high-risk patients in both critical care units and in the operating theatre.
LiDCO sells directly to hospitals in the UK and USA and through a network of speciality critical care and anaesthesia distributors in the rest of the world. LiDCO’s headquarters are in London and its shares are traded on AIM.
For more information: http://www.lidco.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.